Heart Attack - Symptoms | Risk | Facts | Alternatives | Surgery Recovery

Where can I read more on this subject?

If you are interested in reading more on this subject, you may of course take a look at my book „Herzinfarkt – Ein Medizinskandal„.

For those readers who would like to study the subject further, I have included  my publication „On the genesis of myocardial ischemia


  1. Rihal CS, et al.: Indications for coronary artery bypass surgery and percutaneous coronary intervention in chronic stable angina. Circulation (2003), 108:2439-2445
  2. Murphy ML, et al.: Reatment of chronic stable angina. N Engl J Med (1977), 297:621-627
  3. European Coronary Surgery Study Group: Long-Term Results of Prospective Randomised Study of Coronary Artery Bypass Surgery in Stable Angina Pectoris. Lancet (1982), ii:1173-1180
  4. CASS Principle Investigators: Myocardial Infarction and Mortality in the Coronary Artery Surgery Study (CASS) Randomized Trial. N Engl J Med (1984), 310:750-758
  5. Alderman EL, et al.: Ten-Year Follow-up of Survival and Myocardial Infarction in the Randomized Coronary Artery Surgery Study. Circulation (1990), 82:1629-1646
  6. Takaro T, et al.: Survival in Subgroups of Patients with Left Main Coronary Artery Disease. VA Coop Study. Circulation (1982), 66:14-21
  7. McIntosh HD, Garcia JA: The First Decade of Aortocoronary Bypass Grafting, 1967-1977. A Review. Circulation (1978), 57:405-431
  8. Velazquez EJ, et al.: Coronary-Artery Bypass Surgery in Patients with Left Ventricular Dysfunction. N Engl J Med (2011), 364:1607-1616
  9. Fang JC: Underestimated Medical Therapy for Coronary Disease… Again. N Engl J Med (2011), 364:1671-1673
  10. Block TA, et al.: Improvement in exercise performance after unsuccessful myocardial revascularization. Am J Cardiol (1977), 40:673-680
  11. Sroka K: Herzinfarkt vermeiden. Psychosozial Verlag, Gießen, 2002
  12. Kaunitz H: Bedeutung der Nahrungsfette bei der Arteriosklerose. Münch Med Wschr. (1977), 119:539
  13. Kern B: Der Myokardinfarkt. Seine myokardiale Pathogenese und Prophylaxe, dargestellt am Grundriß der Linksmyokardiologie. Haug, Heidelberg, 1969
  14. Glatzel H: Fettverzehr und Koronarkrankheiten. Z Allg Med (1980), 56:445
  15. Schaefer H, et al.: Herzinfarkt-Report 2000. Urban + Fischer, München, Jena, 2000
  16. Baroldi G, Scomazzoni G: Coronary circulation in the normal and pathologic heart. Am Registry of Pathology. Armed Forces Institute of Pathology. Governement Printing Office, Washington D.C., 1967
  17. Sroka K: On the genesis of myocardial ischemia. Z Kardiol (2004), 93:768-783
  18. Wartman WB, Hellerstein HK: The Incidence of Heart Disease in 2,000 Consecutive Autopsies. Ann Intern Med (1948), 28:41-65
  19. Fulton WF: The Coronary Arteries: Arteriography, Microanatomy and Pathogenesis of Obliterative Coronary Artery Disease. Springfield, IL: Charles C Thomas, 1965
  20. Khouri EM, et al.: Flow in the major branches of the left coronary artery during experimental coronary insufficiency in the unanesthetized dog. Circulation Res (1968), 23:99
  21. Schaper W, Pasyk S: Influence of collateral flow on the ischemic tolerance of the heart following acute and subacute coronary occlusion. Circulation (1976), 53 (suppl I): I-57
  22. Mills JD, et al.: Coronary collaterals development during chronic ischemia: serial assessment using harmonic myocardial contrast echocardiography. J Am Coll Cardiol (2000), 36:618
  23. van Royen N, et al.: A Critical Review of Clinical Arteriogenesis Research. J Am Coll Cardiol (2010), 55:17-25
  24. Doerr W, et al.: Neues und Kritisches vom und zum Herzinfarkt. Sitzungsberichte der Heidelberger Akademie der Wissenschaften. Math.-nat. Klasse. Springer, Berlin-Heidelberg-New York, 1974
  25. Murakami T, et al.:Intracoronary aspiration thromectomy for acute myocardial infarction. Am J Cardiol (1998), 82:839-844
  26. DeWood MA, et al.: Prevalence of total coronary occlusion during the early hours of transmural myocardial infarction. N Engl J Med (1980), 303:897-902
  27. DeWood MA,et al..: Coronary arteriographic findings soon after non-Q-wave myocardial infarction. N Engl J Med (1986), 315:417-423
  28. Baroldi G: Significance of morphologic findings in sudden death and acute myocardial infarction. In: Schaefer H, u.a.: Herzinfarkt-Report 2000, Urban + Fischer, München, Jena, 2000
  29. Ambrose JA, et al.: Angiographic progression of coronary artery disease and the developement of myocardial infarction. J Am Coll Cardiol (1988), 12:56-62
  30. Little WC, et al.: Can coronary angiography predict the site of a subsequent myocardial infarction in patients with mild to moderate coronary artery disease? Circulation (1988), 78:1157-1166
  31. Giroud D, et al.: Relation of the site of acute myocardial infarction: implications for coronary angiography. Clin Cardiol (1992), 69:729-732
  32. Fishbein MC, et al.: How big are coronary atherosclerotic plaques that rupture? Circulation (1996), 94:2662-2666
  33. Airaksinen K, et al.: Impaired vagal heart control in coronary artery disease. Br Heart J (1987), 58:592-597
  34. Kop WJ, et al: Changes in heart rate and heart rate variability before ambulatory ischemic events. J Am Coll Cardiol (2001), 38:742-749
  35. Sroka K, et al.: Heart Rate Variability in Myocardial Ischemia During Daily Life. J Electrocardiol (1997), 30:45-56
  36. Williamson JR, Jamieson D: Metabolic effects of epinephrine in the perfused rat heart. I. Comparison of intracellular redox states, tissue pO2, and force of contraction. Mol Pharmacol (1966), 2:191-205
  37. Gollwitzer-Meier K: Reaktionsänderungen im Herzen unter dem Einfluss von Adrenalin. Pflügers Arch (1942), 245:575-583
  38. Collins-Nakai RL, et al.: Epinephrine increases ATP production in hearts by preferentially increasing glucose metabolism. Am J Physiol (1994), 267:H1862-H1871
  39. Levy B: Lactate and shock state: the metabolic view. Curr Opin Crit Care (2006), 12:315-321
  40. Collinson PO, et al.: Multicenter evaluation of the diagnostic value of cardiac troponin T, CK-MB mass, and myoglobin for assessing patients with suspected acute coronary syndromes in routine clinical practice. Heart (2003), 89:280-286
  41. RITA-2 trial participants: Coronary angioplasty versus medical therapy for angina: the second Randomised Intervention Treatment of Angina (RITA-2) trial. Lancet (1997), 350:461-468
  42. RITA-3 investigators: Interventional versus conservative treatment for patients with unstable angina and non-ST-elevation myocardial infarction: the British Heart Foundation RITA 3 randomised trial. Lancet (2002), 360:743-751
  43. Fox KA, et al.: 5-year outcome of an interventional strategy in non-ST-elevation acute coronary syndrome: the British Heart Foundation RITA 3 randomised trial. Lancet (2005), 366:914-920
  44. de Winter RJ, et al.: Invasive versus Conservative Treatment in Unstable Coronary Syndromes (ICTUS) Investigators. N Engl J Med (2005), 353:1095-1110
  45. Sroka K: Herzinfarkt – Neue Wege. BoD, Norderstedt, 2006
  46. Kuklinski B: Zum Petkau-Effekt des Superoxids. Diagnostik- und Therapiezentrum für umweltmedizinische Questionn, Rostock, 2004
  47. Kuklinski B: Antioxidantien in der prophylaktischen und kurativen Medizin. In: Ernährung und Immunfunktion. Herausgeber: Deutscher Kassenarztverbund. Medizinische Public Relations, Gräfelfing, 1995
  48. Kratz, et al.: Effects of dietary fatty acids on the composition and oxidizability of low-density lipoprotein. Eut J Clin Nutr (2002), 56:72-81
  49. Gorbe A, et al.: Role of cGMP-PKG signaling in the protection of neonatal rat cardiac myocytes subjected to simulated ischemia/reoxygenation. Basis Res Cardiol (2010), 105:643-645
  50. Costa AD, et al.: cGMP signaling in pre- and post-conditioning: the role of mitochondria. Cardiovasc Res (2008), 77:344-352
  51. Garlid KD, et al.: Cardioprotective signaling to mitochondria. J Moll Cell Cardiol (2009), 46:858-866
  52. Lei B, et al.: Exogenous nitric oxide reduces glucose transporters translocation and lactate production in ischemic myocardium in vivo. Proc Natl Acad Sci (2005), 102:6966-6971
  53. Burley DS, et al.: Cardioprotective actions of peptide hormones in myocardial ischemia. Heart Fail Rev (2007), 12:279-291
  54. Epstein FH: Low serum cholesterol, cancer and other noncardiovascular disorders. Atherosclerosis (1992), 94:1-12
  55. Weverling-Rijnsburger AWE, et al.: Total cholesterol and risk of mortality in the oldest. Lancet (1997), 358:351-355
  56. Heart Protection Study Colloborative Group: MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebo-controlled trial. Lancet (2002), 360:7-22
  57. Ignarro LJ, et al.: Nitric Oxide Donors and Cardiovascular Agents Modulating the Bioactivity of Nitric Oxide. Circ Res (2002), 90:21-28
  58. Laufs U, et al.: Upregulation of Endothelial Nitric Oxide Synthase by HMG CoA Reductase Inhibitors. Circulation (1998), 97:1129-1135
  59. Moschos CB, et al.: Effect of aspirin upon experimental coronary and non-coronary thrombosis and arrhythmia. Am Heart J (1972), 84:525-530
  60. Teng CM, et al.: YC-1, a nitric oxide-independent activator of soluble guanylate cyclase, inhibits platelet-rich thrombosis in mice. Eur J Pharmacol (1997), 320:161-166
  61. Bode-Böger SM, et al.: Aspirin reduces endothelial cell senescence. Biochem Biophys Res Commun (2005), 334: 1226-1232
  62. Grosser N, Schröder H: Aspirin protects endothelial cell from oxidant damage via the nitric oxide-cGMP pathway. Arterioscler Thromb Vasc Biol (2003), 23:1345-1351
  63. Antiplatelet Trialist‘ Collaboration: Collaborative overview of randomised trials of antiplatelet therapy-I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Br Med J (1994), 308:81-106
  64. Rozanski A, et al.: Impact of Psychological Factors on the Pathogenesis of Cardiovascular Disease and Implications for Therapy. Circulation (1999), 99:2192-2217
  65. Frasure-Smith N, et al.: The Ischemic Heart Disease Life Stress Monitoring Program: Impact on Mortality: Psychosom Med (1985), 47:431-445
  66. Harrison LL, et al.: Effects of early patent touch on preterm infants‘ heart rates and arterial oxygen saturation levels. J Adv Nurs (1990), 15:877-885
  67. McCraty R, et al.: The Effects of Emotions on Short-Term Power Spectrum Analysis of Heart Rate Variability. Am J Cardiol (1995), 76:1089-1093
  68. Dohrmann RE, Dohrmann M: Neuere Therapie der instabilen Angina pectoris bei koronarer Herzerkrankung. Erfahrungsheilkunde – acta medica empirica (1984), 33:183-190
  69. Salz H, Schneider B: Perlinguales g-Strophanthin bei stabiler Angina pectoris. Z f Allgemeinmedizin (1985), 61:1223-1228
  70. Sarre H: Strophanthinbehandlung bei Angina pectoris. Therapiewoche (1952/53), 3:311-314
  71. Brembach H: Infarktvorbeugung in der Arbeitsmedizin. Notabene medici (1984), 7:613-616
  72. Dohrmann RE, et al.: Klinisch-poliklinische Studie über die Wirksamkeit von g-Strophanthin bei Angina pectoris und Myokardinfarkt. Cardiol Bull (1977), 14/15:183-187
  73. Agostini PG, et al.: Long-Term Use of K-Strophantin in Advanced Congestive Heart Failure Due to Dilated Cardiomyopathy: A Double-Blind Crossover Evaluation Versus Digoxin. Clin Cardiol (1994), 17:536-541
  74. Löhr E, et al.: Beitrag zur Membranpermeabilität von Cardiaca (g-Strophanthin, Digoxin und Oxyfedrin) aufgrund von Mikro-Autoradiographien am Meerschweinchenherzen. Arzneimittelforschung (1971), 21:921-927
  75. Weitkamp, et al. (2003): http://www.vetmed.uni-giessen.de/biochem/schoner/Abschiedsvorlesung.html, p.26
  76. Oselkin M, et al.: Low dose cardiotonic steroids increase sodium-potassium ATPase activity that protects hippocampal slice cultures from experimental ischemia. Neurosci Lett (2010), 473:67-71
  77. DeMots H, et al.: Effects of Ouabain on Myocardial Oxygen Supply and Demand in Patients with Chronic Coronary Artery Disease. J Clin Invest (1976), 58:312-319
  78. Gremels H: Über den Einfluß von Digitalisglykosiden auf die energetischen Vorgänge am Säugetierherzen. Arch Exp Path Pharmakol (1937), 186:625-660
  79. Gillis RA, Quest JA: The Role of the Nervous System in the Cardiovascular Effects of Digitalis. Pharmacol Rev (1979), 31:19-97
  80. Slatton ML, et al.: Does digoxin provide additional hemodynamic and autonomic benefit at higher doses in patients with mild to moderate heart failure and normal sinus rhythm? J Am Coll Cardiol (1997), 29:1206-1213
  81. Paton WDM, et al.: The mechanism of acetylcholine release from parasympathetic nerves. J Physiol (1971), 215:819-848
  82. Satoh E, Nakazato Y: On the Mechanism of Ouabain-Induced Release of Acetylcholine from Synaptosomes. J Neurochem (1992), 58:1038-1044
  83. Kull J: Strophanthinwirkung und cholinergischer Mechanismus am Herz. Arch Exp Path Pharmakol (1939), 192:447-456
  84. Pierre SV, et al.: Ouabain triggers preconditioning through activation of the Na+,K+-ATPase signaling cascade in rat hearts. Cardiovasc Res (2007), 73:488-496
  85. Pasdois PP, et al: Ouabain protects rat hearts against ischemia-reperfusion injury via a pathway involving src kinase, mitoK,ATP, and ROS. Am J Physiol (2007), 292:H1470-H1478
  86. Shah Y: Strophanthin – ein besonderes Herzglykosid. Z f Komplementärmedizin (2011), 2:48-51
  87. Shah Y: Heilpflanzenporträt: Strophantus. ZKM (2011), 2:58
  88. Hamlyn J, et al: Welcome to ouabain – a new steroid hormone. Lancet (1991), 338:543-544
  89. Petry RJ: Die Lösung des Herzinfarkt-Problems durch Strophanthin. Frolegium Verlag, Bremen, 2006
  90. Fürstenwerth H: Ouabain – the insulin oft he heart. Clin Pract (2010), 64:1591-1594
  91. Fürstenwerth H: On the differences between ouabain and digitalis glykosides. Am J Therap (2011)
  92. Ruiz G, et al.: Homeopathic effect on heart rate variability. Br Homeopath J (1999), 88:106-111
  93. Huang J, et al.: Heart rate variability depression in patients with unstable angina. Am Heart J (1995), 130:772-779
  94. Liao D, et al.: Cardiac Autonomic Function and Incident Coronary heart Disease: A Population-based Case-Cohort Study. The ARIC Study. Am J Epidemiol (1997), 145:696-706
  95. Tsuji H, et al.: Impact of Reduced Heart Rate Variability on Risk for Cardiac Events. Circulation (1996), 94:2850-2855

Read more about heart attacks, facts, alternatives, prevention, well-being

Is it possible to measure the risk of heart attack?

Back to the questions »